What firms are best positioned to reap profits from the stem cell harvest?
Nature magazine (www.nature.com) named four in an article by Stephan Herrera in its July issue. Here is what he had to say.
"Of course, it's still early days to predict those companies whose position is consolidated best for success. But with their clear advantage in terms of intellectual property positions and current stage of investment and product development, firms like Geron in Menlo Park, California, Osiris Therapeutics in Baltimore, Maryland, NeuroNova in Stockholm and ES Cell International in Singapore will be hard to catch."
Herre also had this to say about venture capitalists.
"Investors, like HealthCap in Stockholm, Allen & Company in New York and MPM in San Francisco, have refused to let the politics and uncertainly of stem cells keep them away. They have an early advantage of those who (quite understandably in this risk-averse, late-stage climate) have steered clear of the field."
Thank you for pulling all this together. One note on "notes from Nature": The article you cite by Stephan Herrera is not from the "July issue" of Nature magazine (a weekly, www.nature.com/nature), as you say, but from the monthly Nature Biotechnology (www.nature.com/nbt). It's a rather different beast. Herrera is Nature Biotechnology's news editor.
ReplyDelete